Back

Effect of beta blocker therapy following myocardial infarction in optimally treated patients in the reperfusion era - a Danish, nationwide, and registry-based cohort study

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Young Investigator Award Session Population Sciences Beta-Blockers ESC Premium Access ESC Congress 2020

About the speaker

Photo
Mr Anders Holt

Herlev and Gentofte Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Regular exercise after a diagnosis of atrial fibrillation and lower risks of cardiovascular disease: a nationwide population-based study
Doctor H. Ahn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
Mr S. Hageman (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
The association of artificial intelligence-enabled electrocardiogram-derived age (physiologic age) with atherosclerotic cardiovascular events in the community
Doctor J. Medina-Inojosa (Atlanta, US)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session Population Sciences
Video

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Webinar
Are beta-blockers still indicated after myocardial infarction?
thumbnail
Congress Presentation
Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction
thumbnail
Congress Presentation
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources